SRR11296737
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013520 | — | cohortA1 | 0.924 |
| 2 | SRR1478032 | GTEX | — | 0.913 |
| 3 | TCGA-CU-A3YL-01A-11R-A22U-07 | — | — | 0.909 |
| 4 | SRR11296732 | — | — | 0.904 |
| 5 | SRR1516040 | — | — | 0.904 |
| 6 | SRR4195693 | — | — | 0.901 |
| 7 | SRR8942981 | — | — | 0.900 |
| 8 | SRR1432343 | GTEX | — | 0.897 |
| 9 | BS_90B22NGP | ATRT | — | 0.897 |
| 10 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |